1-3 of 3
Patricia Greninger
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-based Rational Combinations are Effective in Models of MYCN-amplified Neuroblastoma

Krista M. Dalton, Kateryna Krytska, Timothy L. Lochmann, Renata Sano, Colleen Casey, Alessia D'Aulerio, Qasim A. Khan, Giovanna Stein Crowther, Colin Coon, Jinyang Cai, Sheeba Jacob, Richard Kurupi, Bin Hu, Mikhail Dozmorov, Patricia Greninger, Andrew J. Souers, Cyril H. Benes, Yael P. Mossé, Anthony C. Faber
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (8): 1400–1411.
https://doi.org/10.1158/1535-7163.MCT-20-0710
Published: 01 August 2021
View article titled, Venetoclax-based Rational Combinations are Effective in Models of <em>MYCN</em>-amplified Neuroblastoma
Open the PDF for Venetoclax-based Rational Combinations are Effective in Models of <em>MYCN</em>-amplified Neuroblastoma in another window
Includes: Supplementary data
Journal Articles

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Stuart W. Ember, Que T. Lambert, Norbert Berndt, Steven Gunawan, Muhammad Ayaz, Marilena Tauro, Jin-Yi Zhu, Paula J. Cranfill, Patricia Greninger, Conor C. Lynch, Cyril H. Benes, Harshani R. Lawrence, Gary W. Reuther, Nicholas J. Lawrence, Ernst Schönbrunn
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1054–1067.
https://doi.org/10.1158/1535-7163.MCT-16-0568-T
Published: 01 June 2017
View article titled, Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics
Open the PDF for Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics in another window
Includes: Supplementary data
Journal Articles

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason T. Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR09.
https://doi.org/10.1158/1535-7163.PMS-PR09
Published: 01 May 2014
View article titled, Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models